<DOC>
	<DOCNO>NCT01350336</DOCNO>
	<brief_summary>As Conditions Approval PMA Alair System , FDA require Boston Scientific generate data ass durability BT treatment effect well safety data intend use population United States .</brief_summary>
	<brief_title>Bronchial Thermoplasty Severe Persistent Asthma</brief_title>
	<detailed_description>This multicenter , open-label , single arm study design demonstrate durability treatment effect evaluate short-term longer-term safety profile Alair System United States intend use population ( patient 18 year old severe persistent asthma ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Subject adult age 18 65 year . 2 . Subject able read , understand , sign write Informed Consent participate study able comply study protocol . 3 . Subject asthma take regular maintenance medication include : 1 . Inhaled corticosteroid ( ICS ) dosage great 1000μg beclomethasone per day equivalent , AND long acting β2agonist ( LABA ) dosage ≥80μg per day Salmeterol equivalent . 2 . Other asthma medication leukotriene modifier , antiIgE , acceptable ( Subjects Xolair® must Xolair great 1 year ) . 3 . Oral corticosteroid ( OCS ) dosage , great 10mg per day acceptable . * 4 . Subject prebronchodilator FEV1 great equal 60 % predict . 5 . Subject nonsmoker 1 year great ( former smoker , less 10 pack year total smoking history ) . 6 . Subject able undergo outpatient ( day ) bronchoscopy opinion investigator per hospital guideline . 7 . Subject least 2 day asthma symptom last 4 week . 8 . Subject AQLQ score baseline period 6.25 less . NOTE : Subjects dosage regimen 20mg OCS every day may include equivalent average daily dosage 10mg . 1 . Subject participate another clinical trial within 6 week Baseline Period involve respiratory intervention could affect outcome measure Study . 2 . Over last 7 day 4 week medication stable period , subject requirement rescue medication use prophylactic use exercise exceed average : 1 . 8 puff per day shortacting bronchodilator , 2 . 4 puff per day longacting rescue bronchodilator , 3 . 2 nebulizer treatment per day . At discretion Principal Investigator , subject consider unstable baseline medication may medications adjust reevaluate 4 week medication stabilization period . 3 . Subject postbronchodilator FEV1 le 65 % . 4 . Subject history lifethreatening asthma , define past intubation asthma , ICU admission asthma within prior 2 year . 5 . Subject 3 hospitalization exacerbation asthma previous year . 6 . Subject 4 infection low respiratory tract ( LRTI ) require antibiotic past 12 month . 7 . Subject 4 pulse systemic corticosteroid ( tablet , suspension injection ) asthma symptom past 12 month . 8 . Subject know sensitivity medication require perform bronchoscopy ( lidocaine , atropine benzodiazepine ) . 9 . Subject respiratory disease include emphysema , cystic fibrosis , vocal cord dysfunction , mechanical upper airway obstruction , ChurgStrauss syndrome , allergic bronchopulmonary aspergillosis ( asthma , immediate cutaneous reactivity A. fumigatus , total serum IgE &gt; 1000ng/mL , elevate specific IgE IgG A. fumigatus without evidence central bronchiectasis ) . 10 . Subject segmental atelectasis , lobar consolidation , significant unstable pulmonary infiltrate , pneumothorax , confirm xray . 11 . Subject currently clinically significant cardiovascular disease , include myocardial infarction , angina , cardiac dysfunction , cardiac dysrhythmia , conduction defect , cardiomyopathy , stroke . 12 . Subject know aortic aneurysm . 13 . Subject significant comorbid illness cancer , renal failure , liver disease , cerebral vascular disease . 14 . Subject uncontrolled hypertension ( &gt; 200mm Hg systolic &gt; 100mm Hg diastolic pressure ) . 15 . Subject implanted electrical stimulation device ( e.g. , pacemaker , cardiac defibrillator , deep nerve deep brain stimulator ) . 16 . Subject coagulopathy ( INR &gt; 1.5 ) . 17 . Subject medical condition would make inappropriate study participation , Investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>